Synpromics Blog The future of gene therapy is in controlling the genetic pay load

Synpromics' CEO presents at the ARM Cell & Gene Therapy Investor DayDavid Venables presented to a full room of investors at the ARM Cell & Gene Therapy Investor Day in New York. Watch David's presentation below or view the pdf here.As well as a great selection of companies sharing their progress, David managed to fit in some promising partnering meetings. His key take-away from the day was "People are starting to understand that the future of gene therapy is in controlling the genetic pay load." Encouraging signs of future developments in cell and gene medicine. Tweet